Articles tagged with Diabetic Retinopathy
A novel intraocular therapy has been shown to prevent or reverse diabetic retinopathy in mice by increasing ACE-2 expression. The study found that the therapy reduced pro-inflammatory cells and reversed vascular degeneration, suggesting a potential new treatment for blindness and other vascular diseases.
A new study reveals that nerve damage occurs before vessel damage in the retina due to diabetes, contradicting long-held beliefs. This finding has significant implications for treatment and prevention strategies.
A study by Mass. Eye and Ear researchers describes an association between a defective myogenic response in blood vessels of the retina and early development of diabetic retinopathy in patients with type 1 diabetes. The findings provide a potential target for therapies to delay or prevent accelerated onset diabetic retinopathy.
Ultrawide field (UWF) scanning technology improved the ability to identify diabetic retinopathy in patients and judge the need for follow-up examinations or treatment. The study found that UWF imaging reduced ungradable images by 81% compared to traditional digital retinal photographs.
Researchers have found ranibizumab to be an effective alternative to laser therapy for treating proliferative diabetic retinopathy, a disease that causes extensive harm to the blood vessels in the retina. The drug carries fewer side effects and improves vision by about half a line on an eye chart compared to the laser group.
A new study suggests that intravitreous ranibizumab injections may be a reasonable treatment alternative to panretinal photocoagulation (PRP) at least through 2 years for patients with proliferative diabetic retinopathy. The study found that ranibizumab met noninferiority outcomes in visual acuity change compared to PRP.
A clinical trial has found that ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy, with patients showing improved central vision and reduced risk of surgery compared to laser therapy. The study also suggests that Lucentis may help prevent diabetic macular edema.
A clinical trial funded by the National Institutes of Health found that Lucentis is highly effective in treating proliferative diabetic retinopathy, improving vision by about half a line on an eye chart compared to laser therapy. The study also showed lower rates of complications such as vitrectomy and serious systemic adverse events.
Researchers found that advanced diabetic eye disease remains low among children living with diabetes, regardless of disease duration. They recommend delaying annual screenings until age 15 or 5 years after diagnosis for most children with type 1 diabetes.
Eyes with peripheral diabetic retinal lesions have a three-fold increased risk of progression to advanced stages of vision-threatening diabetic retinopathy. The findings suggest that wider field imaging may change how diabetic eye disease is evaluated and treated.
Researchers have evaluated the best potential sources for adult stem cells to be used for treating diabetic retinopathy. They found that cells taken from donors without diabetes are more effective than those from patients' own bodies. This discovery provides a crucial framework for evaluating stem cells for future treatments.
Researchers at Johns Hopkins University and the University of Maryland have discovered a new way to treat diabetic retinopathy by blocking two growth proteins, VEGF and angiopoietin-like 4. This could prevent many cases of proliferative diabetic retinopathy, which is the most common cause of vision loss in working-age adults in the US.
A clinical trial comparing Eylea (aflibercept), Avastin (bevacizumab), and Lucentis (ranibizumab) for diabetic macular edema found that Eylea provided greater visual improvement, especially in patients with moderate vision loss. The study enrolled 660 participants and showed similar results when starting vision was mild.
A new study published in JAMA Ophthalmology found that telemedicine screening detected diabetic retinopathy in approximately 21.7% of the participants, highlighting its potential as a critical tool for patients with diabetes who face barriers to accessing regular eye care.
The Champalimaud Award recognizes the development of Anti-Angiogenic Therapy for Retinal Disease, which has improved vision in patients with devastating blindness diseases. The treatment targets age-related macular degeneration and diabetic retinopathy, conditions affecting millions worldwide.
Researchers have developed a novel strategy to diagnose diabetic retinopathy by detecting the early molecular changes caused by diabetes on the endothelium of retinal vessels. This allows for early detection and potential intervention to prevent irreversible structural damage.
A new study from USC Eye Institute reveals that Native American ancestry is a significant risk factor for vision-threatening diabetic retinopathy among Latinos with Type 2 diabetes. The research found individuals with more than 50% Native American ancestry had an 87% higher chance of developing severe diabetic retinopathy.
Researchers discovered that dopamine-restoring drugs can improve visual function in animal models of diabetes. The study found that L-DOPA and dopamine receptor agonists improved acuity and contrast sensitivity, offering new avenues for treating diabetic retinopathy.
A study by researchers at the Medical College of Georgia has identified two players that must work together to destroy vision in patients with diabetes. The findings suggest that blocking the production of reactive oxygen species by either retinal cells or white blood cells may be a viable strategy for intervention.
A study published in Neural Regeneration Research found that endoplasmic reticulum stress plays a crucial role in the death of ganglion cells and impairment of retinal microvessels in diabetic retinopathy. Tauroursodeoxycholic acid treatment effectively inhibited this pathway, providing protection against diabetic retinopathy.
A new Clinical Practice Guideline recommends that all pregnant women with no prior diagnosis of diabetes be tested for the condition at their first prenatal visit. Early detection can help prevent complications and ensure a healthy pregnancy. The guideline also provides recommendations for testing, treatment, and follow-up care for wom...
A new study found that adults with diabetes in Ontario are getting significantly fewer government-funded eye exams than they were a decade ago. The decrease is an unintended consequence of the provincial government's decision in 2004 to delist routine eye exams from the Ontario Health Insurance Plan for healthy adults under age 65.
Researchers found that combining insulin and an EGF inhibitor preserved vascular integrity in diabetic mice, limiting vision damage from diabetic macular edema. The study suggests a potential therapeutic combination to prevent DME in people with diabetes.
Researchers have identified a compound that could prevent damage to the retina in diabetic retinopathy by targeting two important pathways: inflammation and blood vessel weakening. The finding is promising for developing a new therapy.
A Wayne State University researcher is investigating the role of Nrf2-KEAP1 in diabetic retinopathy. The study aims to understand how diabetes causes oxidative stress and damage to mitochondria, ultimately accelerating cell death and developing retinopathy.
Research at Peninsula College of Medicine and Dentistry found that screening people with type 2 diabetes every two years is a safe and cost-effective strategy, reducing costs by around 25%. This approach could benefit 2.8m people in the UK who have diabetes.
A $3.9 million grant will enable research to identify protective factors that prevent diabetes complications in long-term insulin-dependent diabetes patients. The study aims to find biomarkers and therapeutic agents to halt diabetic retinopathy and nephropathy, which significantly impact lifespan and quality of life.
Researchers at UBC have developed a novel drug delivery device that can be implanted behind the eye to treat retinal damage caused by diabetes. The device uses an external magnetic field to trigger controlled release of drugs, offering improvements over existing implantable devices.
Fenretinide shows promise in reducing risk of wet AMD and geographic atrophy growth in dry AMD patients. Long-term diabetics who survived over 50 years with type 1 diabetes appear to be protected against PDR, with protective mechanisms activated early in the disease.
A study estimates nearly 30% of US adults over 40 with diabetes have diabetic retinopathy, a leading cause of blindness. The study also reveals higher prevalence and risk factors for vision-threatening retinopathy among diverse populations.
The ACCORD Eye Study found that intensive blood sugar control and combination lipid therapy with a fibrate and statin slowed diabetic retinopathy progression by about one-third. This study provides evidence for the benefits of these therapies in slowing eye disease progression.
The ACCORD Eye Study found that intensive blood sugar control and combination lipid therapy slowed diabetic retinopathy progression by about one-third. Combination therapy reduced disease progression compared to statin therapy alone.
The Los Angeles Latino Eye Study found that US Latinos develop visual impairment, blindness, diabetic eye disease, and cataracts at higher rates than non-Hispanic whites. Researchers also identified specific risk factors for these conditions, including diabetes and age.
Scientists have identified 65 abnormal proteins in diabetic mice that are reversed by treatment with the ARB medication candesartan. The study, published in Journal of Proteome Research, provides new insights into the potential benefits of high blood pressure drugs in preventing and treating diabetic retinopathy.
A Michigan State University scientist has discovered the process that causes retinal cells to die, leading to diabetic retinopathy. The siah-1 protein serves as a type of chauffeur for another protein, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), shuttling it into the nucleus of Müller cells, causing vascular damage.
Interleukin-6 is a key mediator of inflammation in diabetic retinopathy, inducing vascular inflammation and tissue destruction. An interleukin-6 antibody may prevent damage by targeting this inflammatory response.
Research finds that African-American patients with type 1 diabetes who consume more calories and sodium are more likely to develop vision-threatening retinopathy. Low caloric and sodium intakes may have a beneficial effect on the progression of diabetic retinopathy in this population.
Researchers found that injecting triamcinolone into the eye may slow proliferative diabetic retinopathy progression, but not macular edema. Steroid treatments reduced the risk of retinopathy progression without significantly improving vision outcomes.
Researchers found that injecting corticosteroids into the eye slowed the progression of diabetic retinopathy in a study involving 840 eyes. The treatment reduced the risk of vision loss associated with proliferative diabetic retinopathy, which affects 700,000 Americans annually.
A study published in the Journal of Ocular Pharmacology and Therapeutics reveals Pycnogenol improves microcirculation, retinal edema, and visual acuity in early stages of diabetic retinopathy. Visual acuity improved by 17/20 after two months of treatment.
Researchers discovered a link between Wnt signaling pathway activation and diabetic retinopathy. Pro-NGF may play a pathogenic role in Alzheimer disease through oxidative stress-induced modifications. Abnormal endothelial cells contribute to tumor progression and metastasis in cancer.
Studies suggest ophthalmologists should suspect visual variant Alzheimer's in patients with unusual or severe vision problems, particularly difficulty reading. Nearsighted individuals may be less susceptible to diabetic retinopathy due to reduced risks associated with longer axial length and deeper anterior eye chamber.
Researchers at Medical College of Georgia say blocking a protein that battles infection may help prevent a common cause of vision loss in chronic diseases like diabetes. The protein interleukin-6 prompts inflammation, which can lead to complications such as diabetic retinopathy.
Researchers analyzed data from studies on type 1 diabetes to find that intensive treatment can significantly reduce the risk of complications. The study showed improved outcomes in patients treated with more intensive therapy.
A new study found that patients with diabetes and retinopathy have a strong association with obstructive sleep apnea, suggesting a link between the two conditions. The researchers recommend that doctors and nurses consider screening for OSA in type 2 diabetes patients with retinopathy.
A recent study published in The Lancet found that calcium dobesilate did not prevent the development of clinically significant macular oedema (CSME) in patients with mild-to-moderate diabetic retinopathy. In fact, patients who received calcium dobesilate were more likely to develop CSME than those given a placebo.
A UK study found South Asians with type 2 diabetes are more likely to develop diabetic retinopathy, leading to early vision loss. The study also revealed that South Asian patients were significantly younger when diagnosed with diabetes and developed retinopathy about seven years earlier than White Europeans.
The number of Americans with diabetic retinopathy is projected to triple by 2050, while cataracts will increase by 235% and glaucoma among elderly Hispanic individuals will increase 12-fold. Ophthalmologists must collaborate with other clinicians to help patients control their diabetes before eye complications worsen.
Researchers describe a potential new therapeutic approach for diabetic retinopathy using ASP-440, a protease plasma kallikrein inhibitor. The study showed significant reductions in retinal vascular permeability and blood pressure in rodents, suggesting promising results for treating the condition.
Diabetic retinopathy, cataracts, and glaucoma cases among Americans with diabetes are estimated to increase significantly by 2050. The number of people with diabetes-related retinal disease is projected to rise, causing vision loss and disabilities that can lead to depression, reduced mobility, and reduced quality of life.
People with diabetes are at higher risk of visual impairment due to diabetic retinopathy and other ocular conditions. Approximately 11% of American adults with diabetes have some form of visual impairment, compared to 5.9% without the disease.
Scientists have created the first genetic research model for a microscopic part of the eye that causes blindness. The new model aims to test drug compounds and therapeutic agents to prolong the life of receptor cells and delay or prevent blindness.
Researchers discover that a certain drug, known for its pain-relieving properties, can protect the retina from damage caused by diabetes. The study found that sigma receptor activation helps prevent retinal damage and vision loss.
A new vision screening device can detect metabolic stress in the retina, potentially identifying diabetes early. The instrument measures flavoprotein autofluorescence (FA) activity to detect abnormal metabolism and tissue damage.
Hispanic patients with diabetes are less likely to receive eye exams and are often unaware of the ocular complications of diabetes. The study found that nearly half of those with diabetes for more than a year had never had a dilated eye exam.
Patients with diabetes who take rosiglitazone may be less likely to develop proliferative diabetic retinopathy or experience visual acuity loss. The medication delays the formation of new blood vessels and preserves vision.
Researchers found a blood vessel protein, Robo4, that reverses or prevents damage from two devastating eye diseases. The study's discovery could lead to new drugs to treat and prevent age-related macular degeneration and diabetic retinopathy.
A recent study suggests that current FPG thresholds for diagnosing diabetes may not accurately detect diabetic retinopathy, which can lead to blindness. The researchers found that over 60% of retinopathy cases were missed by the widely used diabetes cutoff of 7.0mmol/L.
Two transporters, SMCT1 and SMCT2, can circumvent the blood-retinal barrier to deliver lactate and ketone bodies to a healthy eye, potentially preventing neuronal cell damage. Understanding these transporters' activity may enable early diagnosis of diabetic retinopathy and natural delivery mechanisms for drugs.
A study published in The Lancet found that fenofibrate reduces the frequency of first laser treatment for macular oedema and proliferative DR by 31% and 30%, respectively. These findings suggest additional mechanisms of benefit beyond lipid-lowering effects, potentially additive to blood glucose and blood pressure control.